Glucocorticoid-resistance_NN
in_IN
peripheral-blood_JJ
lymphocytes_NNS
does_VBZ
not_RB
correlate_VB
with_IN
number_NN
of_IN
affinity_NN
of_IN
glucocorticoid-receptors_NNS
in_IN
chronic_JJ
renal_JJ
failure_NN
patients_NNS
._.

Glucocorticoid_NN
-LRB-_-LRB-
GC_NN
-RRB-_-RRB-
resistance_NN
in_IN
patients_NNS
with_IN
chronic_JJ
renal_JJ
failure_NN
-LRB-_-LRB-
CRF_NN
-RRB-_-RRB-
seriously_RB
impairs_VBZ
successive_JJ
GC_NN
therapy_NN
after_IN
renal_JJ
transplantation_NN
._.

We_PRP
examined_VBD
the_DT
relationship_NN
between_IN
GC-receptor_NN
-LRB-_-LRB-
GC-R_NN
-RRB-_-RRB-
parameters_NNS
in_IN
peripheral-blood_JJ
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
PBMC_NN
-RRB-_-RRB-
and_CC
PBMC_NN
resistance_NN
to_TO
GC_NN
in_IN
21_CD
CRF_NN
patients_NNS
and_CC
18_CD
healthy_JJ
subjects_NNS
._.

Each_DT
subject_NN
group_NN
was_VBD
divided_VBN
into_IN
two_CD
subgroups_NNS
according_VBG
to_TO
PBMC_NN
sensitivity_NN
to_TO
prednisolone_NN
in_IN
a_DT
mitogen_NN
assay_NN
procedure_NN
;_:
i.e._FW
,_,
sensitive_JJ
-LRB-_-LRB-
IC50_NN
&lt;_JJR
381_CD
ng\/mL_NN
-RRB-_-RRB-
and_CC
resistant_JJ
-LRB-_-LRB-
IC50_NN
&gt;_JJR
381_CD
ng\/mL_NN
-RRB-_-RRB-
groups_NNS
._.

In_IN
healthy_JJ
subjects_NNS
,_,
the_DT
mean_JJ
GC-R_NN
Bmax_NN
and_CC
Kd_NN
in_IN
quiescent_JJ
PBMC_NN
of_IN
the_DT
GC-sensitive_JJ
group_NN
were_VBD
2.89_VBG
+_CC
\/_JJ
-_CC
1.23_CD
fmol\/10_NN
6_CD
cells_NNS
and_CC
4.00_CD
+_CC
\/_CD
-_:
2.24_CD
nM_NN
,_,
respectively_RB
._.

The_DT
Bmax_NN
in_IN
these_DT
subjects_NNS
significantly_RB
increased_VBD
to_TO
6.61_CD
+_CC
\/_CD
-_:
2.02_CD
-LRB-_-LRB-
257.7_CD
+_CC
\/_CD
-_:
107.8_CD
%_NN
-RRB-_-RRB-
after_IN
24_CD
h_NN
stimulation_NN
with_IN
concanavalin_NN
A_NN
-LRB-_-LRB-
p_NN
&lt;_JJR
0.01_CD
-RRB-_-RRB-
,_,
while_IN
the_DT
Kd_NN
change_NN
was_VBD
not_RB
significant_JJ
._.

The_DT
GC-R_NN
Bmax_NN
and_CC
Kd_NN
in_IN
quiescent_JJ
PBMC_NN
of_IN
the_DT
GC-resistant_JJ
group_NN
were_VBD
5.33_VBG
+_CC
\/_JJ
-_CC
1.37_CD
fmol\/10_NN
6_CD
cells_NNS
and_CC
3.20_CD
+_CC
\/_CD
-_:
1.39_CD
nM_NN
,_,
respectively_RB
._.

Both_DT
of_IN
these_DT
parameters_NNS
,_,
however_RB
,_,
did_VBD
not_RB
change_VB
significantly_RB
after_IN
mitogen_NN
stimulation_NN
._.

There_EX
was_VBD
a_DT
significant_JJ
negative_JJ
correlation_NN
between_IN
IC50S_NN
of_IN
prednisolone_NN
and_CC
increase-ratios_NN
-LRB-_-LRB-
post\/pre_JJ
ratio_NN
-RRB-_-RRB-
of_IN
Bmax_NN
after_IN
mitogen_NN
stimulation_NN
-LRB-_-LRB-
p_NN
&lt;_JJR
0.05_CD
-RRB-_-RRB-
._.

In_IN
CRF_NN
patients_NNS
,_,
Bmax_NN
and_CC
Kd_NN
in_IN
quiescent_JJ
PBMC_NN
of_IN
the_DT
GC-sensitive_JJ
group_NN
were_VBD
6.04_VBG
+_CC
\/_JJ
-_CC
2.35_CD
fmol\/10_NN
6_CD
cells_NNS
and_CC
3.49_CD
+_CC
\/_CD
-_:
1.72_CD
nM_NN
,_,
respectively_RB
,_,
while_IN
those_DT
in_IN
PBMC_NN
of_IN
the_DT
GC-resistant_JJ
group_NN
were_VBD
5.13_VBG
+_CC
\/_JJ
-_CC
2.31_CD
fmol\/10_NN
6_CD
cells_NNS
and_CC
4.04_CD
+_CC
\/_CD
-_:
1.62_CD
nM_NN
,_,
respectively_RB
._.

The_DT
Bmax_NN
and_CC
Kd_NN
were_VBD
not_RB
significantly_RB
changed_VBN
after_IN
mitogen_NN
stimulation_NN
in_IN
both_DT
subgroups_NNS
of_IN
CRF_NN
._.

Moreover_RB
,_,
in_IN
contrast_NN
to_TO
healthy_JJ
subjects_NNS
,_,
there_EX
was_VBD
no_DT
correlation_NN
between_IN
IC50_NN
and_CC
GC-R_NN
parameters_NNS
in_IN
CRF_NN
._.

We_PRP
concluded_VBD
that_IN
,_,
in_IN
healthy_JJ
subjects_NNS
,_,
decreased_VBN
PBMC_NN
capacity_NN
to_TO
amplify_VB
GC-R_NN
numbers_NNS
in_IN
response_NN
to_TO
mitogen_NN
is_VBZ
correlated_VBN
with_IN
GC_NN
resistance_NN
,_,
whereas_IN
in_IN
CRF_NN
patients_NNS
the_DT
resistant_JJ
mechanism_NN
is_VBZ
not_RB
correlated_VBN
with_IN
GC-R_NN
parameters_NNS
._.

An_DT
unknown_JJ
event_NN
might_MD
be_VB
involved_VBN
in_IN
GC-resistance_NN
of_IN
CRF_NN
._.

